UK's Office of Technology Commercialization (OTC), on behalf of UK Research Foundation (UKRF), was awarded a three-year $600,000 grant from the Economic Development Administration (EDA) Build to Scale Program, one of 52 projects funded from 36 states.
“This project will allow us to significantly reduce the complexity and cost of CO2 capture and biofixation from all sources, whether it is from utility companies, cement manufacturing, or chemical plants."
“This is a great opportunity to carry our efforts beyond Kentucky and the United States,” said Seth DeBolt, director of the James B. Beam Institute for Kentucky Spirits. “To partner with such an established institute will elevate the efforts we’ve already begun at the Beam Institute.”
While the collaborative research between Beam Suntory and the Beam Institute looks at issues with specific distilleries, it also looks at how its operations as well as outside activities impact the local watershed and how to ensure it is properly cared for.
The funding will further ongoing substance use disorder treatment research in collaboration with Sharon Walsh at the UK Center on Drug and Alcohol Research (CDAR) and Mei-Chuan Ko at the Wake Forest School of Medicine.
PDS0203 stands out among COVID-19 vaccines currently in development because it includes a vaccine technology pioneered by PDS Biotech called Versamune®, which stimulates important parts of the immune system to activate T cells.
“We all want to grow Kentucky’s tech sector and create the high-paying, knowledge-based jobs that follow. A big part of doing so is turning Kentucky’s own academic research and development capabilities into commercially viable products and startups.”
Supported by XLerateHealth, a health care startup accelerator in Louisville, Kentucky, and by UK, EnRICH is an outgrowth of NIH funding UK received in October 2018 — $3.5 million over three years — to create the XLerator Network.
The new potential treatment has been added to the University of Kentucky’s innovative clinical trial for experimental COVID-19 therapies, which was launched by leaders from UK’s Markey Cancer Center, College of Medicine and College of Pharmacy in May.